CLINICAL TRIALS PROFILE FOR OMNIPAQUE 300
✉ Email this page to a colleague
All Clinical Trials for Omnipaque 300
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00478556 ↗ | Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT | Completed | GE Healthcare | Phase 4 | 2007-08-01 | Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents. |
NCT00478556 ↗ | Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT | Completed | University of Alabama at Birmingham | Phase 4 | 2007-08-01 | Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents. |
NCT00587132 ↗ | Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma | Terminated | ChiRhoClin, Inc. | Phase 1/Phase 2 | 2006-11-01 | The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population. |
NCT00587132 ↗ | Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma | Terminated | Mayo Clinic | Phase 1/Phase 2 | 2006-11-01 | The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Omnipaque 300
Condition Name
Condition Name for Omnipaque 300 | |
Intervention | Trials |
Lung Cancer Non-Small Cell Cancer (NSCLC) | 1 |
Augmented Renal Clearance | 1 |
Glomerular Filtration Rate | 1 |
Lung Cancer Small Cell Lung Cancer (SCLC) | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for Omnipaque 300
Trials by Country
Clinical Trial Progress for Omnipaque 300
Clinical Trial Phase
Clinical Trial Sponsors for Omnipaque 300
Sponsor Name